8-K: Femasys Regains Nasdaq Listing Compliance

Femasys Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 reverse stock split.

Summary

• Femasys Inc. received formal notice from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2).
• The company previously failed to maintain the required $1.00 minimum bid price, a deficiency first noted on July 16, 2025.
• Compliance was achieved following a 1-for-20 reverse stock split effective June 5, 2026.
• The stock maintained a closing bid price at or above $1.00 for 10 consecutive business days to satisfy the requirement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it removes the immediate threat of delisting, it highlights the underlying share price weakness that necessitated a 1-for-20 reverse split.

Positives

• Removal of the threat of delisting from the Nasdaq Capital Market.
• Successful execution of a reverse stock split to stabilize share price.
• Management focus has shifted back to strategic priorities and commercialization of reproductive health solutions.

Negatives

• The company required a 1-for-20 reverse stock split to meet basic listing requirements, indicating significant downward pressure on the share price over the preceding year.

Risks

• Ongoing reliance on the successful enrollment and completion of the FINALE pivotal trial for FemBloc.
• Uncertainty regarding future regulatory approvals for FemBloc in the U.S. market.
• Execution risk related to commercializing products and establishing sales growth.
• Potential for future share price volatility.

Future Outlook

The company remains focused on advancing strategic priorities, expanding access to reproductive health solutions, and continuing the FINALE pivotal trial for FemBloc.

Management Comments

• Regaining compliance with Nasdaq's continued listing requirements is an important development for Femasys and our shareholders.
• With this matter now closed, we remain focused on advancing our strategic priorities, expanding access to our innovative reproductive health solutions and building long-term value.

Industry Context

StockSavvy.ai notes that regaining compliance is a standard corporate housekeeping event for small-cap biotech firms that have faced prolonged share price weakness. While it removes immediate delisting risk, it does not fundamentally change the company's cash burn or clinical trial execution risks.

Comparison to Industry Standards

• The use of a reverse stock split to regain Nasdaq compliance is a common, albeit often dilutive-perception, strategy used by micro-cap and small-cap biotech companies to avoid delisting.
• The company's reliance on clinical trial milestones (FINALE trial) is consistent with the risk profile of early-stage medical device and reproductive health innovators.

Stakeholder Impact

• Shareholders: Delisting risk removed, though the reverse split reduced the total number of shares held.
• Investors: Increased stability in trading status on the Nasdaq.

Next Steps

• Continued enrollment in the FINALE pivotal trial (NCT05977751).
• Ongoing commercialization efforts for FemaSeed and other fertility products.

Key Dates

Recommendation

The filing confirms a technical resolution to a listing issue. Investors should focus on the progress of the FINALE clinical trial rather than this administrative update, as the long-term value remains tied to product commercialization and regulatory success.

Keywords

Femasys, FEMY, Nasdaq, Compliance, Reverse Stock Split, Reproductive Health, FemBloc, Biomedical